Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.

[1]  César Martín,et al.  Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR , 2020, Scientific Reports.

[2]  A. Di Costanzo,et al.  Autosomal recessive hypercholesterolemia: update for 2020. , 2020, Current opinion in lipidology.

[3]  C. Aguilar-Salinas,et al.  Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. , 2020, JAMA cardiology.

[4]  M. D. Di Minno,et al.  A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia , 2020, Journal of clinical medicine.

[5]  G. Watts,et al.  Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities , 2020, Journal of internal medicine.

[6]  U. Toscanini,et al.  Functional analysis of six uncharacterised mutations in LDLR gene. , 2019, Atherosclerosis.

[7]  D. Gaudet,et al.  Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity , 2019, Arteriosclerosis, thrombosis, and vascular biology.

[8]  W. März,et al.  Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. , 2019, Atherosclerosis.

[9]  Carmen Rodríguez-Jiménez,et al.  Functional analysis of new variants at the low‐density lipoprotein receptor associated with familial hypercholesterolemia , 2019, Human mutation.

[10]  G. Watts,et al.  A cross-national investigation of cardiovascular survival in homozygous familial hypercholesterolemia: The Sino-Roman Study. , 2019, Journal of clinical lipidology.

[11]  César Martín,et al.  Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants , 2018, International journal of molecular sciences.

[12]  M. Gagliardi,et al.  Treatment of homozygous familial hypercholesterolaemia in paediatric patients: A monocentric experience , 2018, European journal of preventive cardiology.

[13]  C. Sirtori,et al.  Autosomal Recessive Hypercholesterolemia: Long-Term Cardiovascular Outcomes. , 2018, Journal of the American College of Cardiology.

[14]  Tommaso Fasano,et al.  The study of familial hypercholesterolemia in Italy: A narrative review. , 2017, Atherosclerosis. Supplements.

[15]  M. Arca,et al.  Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. , 2017, Atherosclerosis. Supplements.

[16]  D. Noto,et al.  Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). , 2017, Atherosclerosis. Supplements.

[17]  C. Sirtori,et al.  Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy , 2017, Advances in Therapy.

[18]  J. Chambers,et al.  Recommendations on the Echocardiographic Assessment of Aortic Valve Stenosis: A Focused Update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. , 2017, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[19]  J. Kastelein,et al.  Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia. , 2017, Journal of clinical lipidology.

[20]  E. Bruckert,et al.  Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France. , 2017, Atherosclerosis.

[21]  N. Plana,et al.  Homozygous Familial Hypercholesterolemia in SpainCLINICAL PERSPECTIVE , 2016 .

[22]  J. Kastelein,et al.  Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease. , 2016, Journal of clinical lipidology.

[23]  C. Stefanutti,et al.  Management of homozygous familial hypercholesterolemia in real-world clinical practice: A report of 7 Italian patients treated in Rome with lomitapide and lipoprotein apheresis. , 2016, Journal of clinical lipidology.

[24]  L. Pérez de Isla,et al.  Clinical and molecular characteristics of homozygous familial hypercholesterolemia patients: Insights from SAFEHEART registry. , 2016, Journal of clinical lipidology.

[25]  F. Raal,et al.  Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. , 2016, Atherosclerosis.

[26]  T. Aitman,et al.  Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes. , 2015, Atherosclerosis.

[27]  G. Watts,et al.  Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia , 2015, Drugs.

[28]  Gerald F. Watts,et al.  Homozigot ailevi hiperkolesterolemi: klinisyenlerin taniyi ve klinik yönetimi gelistirmelerine yönelik yeni anlayislar ve rehberlik. Avrupa Ateroskleroz Dernegi'nin Ailevi Hiperkolesterolemi Üzerine Uzlasi Paneli yazili görüsü. , 2015 .

[29]  E. Sijbrands,et al.  Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. , 2015, European heart journal.

[30]  M. Arca,et al.  The history of Autosomal Recessive Hypercholesterolemia (ARH). From clinical observations to gene identification. , 2015, Gene.

[31]  M. Yamagishi,et al.  Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. , 2014, Atherosclerosis.

[32]  J. Ordovás,et al.  Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. , 2014, Journal of the American College of Cardiology.

[33]  R. Fresa,et al.  Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. , 2013, Atherosclerosis.

[34]  G. Watts,et al.  Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. , 2012, The Journal of clinical endocrinology and metabolism.

[35]  F. Raal,et al.  Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. , 2012, Atherosclerosis.

[36]  A. Soutar,et al.  Mechanisms of Disease: genetic causes of familial hypercholesterolemia , 2007, Nature Clinical Practice Cardiovascular Medicine.

[37]  Jonathan C. Cohen,et al.  Autosomal Recessive Hypercholesterolemia Caused by Mutations in a Putative LDL Receptor Adaptor Protein , 2001, Science.

[38]  F. Raal,et al.  Lipoprotein(a) in homozygous familial hypercholesterolemia. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[39]  S. Bertolini,et al.  Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia. , 1999, Arteriosclerosis, thrombosis, and vascular biology.